literature

HIV mutation literature information.

Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

PMID: 26574015 2016 Antimicrobial agents and chemotherapy

Abstract: All viruses containing RT-M184V were resistant to FTC (>1,000-fold).

Abstract: As a follow-up, the in vitro characteristics of mutant HIV-1 containing RT-K65R and/or RT-M184V with IN-Q148R or IN-N155H were also evaluated, alone and in combination, for potential interactions.

Abstract: In clinical trials of coformulated elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF), emergent drug resistance predominantly involved the FTC resistance substitution M184V/I in reverse transcriptase (

CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.

PMID: 26584666 2016 Tropical medicine & international health

Abstract: RESULTS: Fewer patients with the M184V mutation reached immunologic failure criteria than those without: 51 of 151(34%) vs.

Abstract: The CD4 count decline among patients with the M184V mutation was 2.5 cells/mm(3) /year, whereas in those without M184V it was 14 cells/mm(3) /year (P = 0.1), but the difference in CD4 count decline with and without NNRTI resistance was marginal.

Abstract: We investigated the association of M184V and NNRTI resistance with WHO immunological failure criteria and CD4 count trends, using chi-square tests and linear mixed models.

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

PMID: 26651266 2016 AIDS research and human retroviruses

Result: Major signature NRTI mutations against TDF and FTC M184V (0.8%, n = 35), M184I (0.07%, n = 3), K65R (0.07%, n = 3), and K70E (0.04%, n = 2) were rarely observed.

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.

PMID: 26731753 2016 AIDS (London, England)

Result: As reported previously, only 5 of the 9 cases of resistance had both evidence of PrEP use (detectable levels of tenofovir) and resistance to the PrEP drugs they were taking (FTC selects for K65R and M184IV; TDF selects for K65R and K70E), suggesting that the resistance mutations detected in these 5 seroconverters were likely due to PrEP selection.

Result: Case 2-283 had M184V in 16% of virus variants when seroconversion was detected and 1.7% M184V 1 month later, which faded below 1% by 6 months and remained undetectable through 24 months.

Result: The other 4 cases of PrEP-selected resistance were individuals randomized to FTC/TDF (2 individuals with unrecognized acute infection at randomization: 3-269 and 2-331; and 2 individuals who acquired HIV post-randomizatio

Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation.

PMID: 26751207 2016 PloS one

Abstract: Analysis of mutations at four HIV-1 DR codons (K103N, Y181C, M184V, and G190A) in 26 blood specimens showed a strong correlation of the ratios of mutant signal to total signal between the paper CDD and the plate CDD.

Result: Clinical specimens (N = 26) from Kenyan's infected with HIV-1 subtypes A, C, D, AE and G, and plasmid standards at 0, 5 and 50% MUT were tested for drug resistance mutations at four HIV codons (K103N, Y181C, M184V and G190A, N total = 104) by both paper CDD and plate CDD OLA (Figs 4 and 5).

Figure: Analysis of clinical specimens and plasmid standards by paper capture, denaturation, and detection (CDD) and plate CDD for mutations M184V and

Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.

PMID: 26803719 2016 The Journal of antimicrobial chemotherapy

Abstract: Seventy-four subjects (82%) harboured the mutation M184V/I and the median number of thymidine-associated mutations was 3 (IQR: 0-4).

Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay.

PMID: 26828876 2016 PloS one

Abstract: By multiple stepwise logistic regression, factors associated with undetectable HIV RNA after 6 months of ART were: having M184V/I (odds ratio [OR] 0.11; 95% confidence interval [CI] 0.02-0.62, p = 0.013), condom use (OR 2.38; 95% CI 1.12-5.06, p = 0.024), and adherence per 5% increase (OR 1.16; 95% CI 1.00-1.35, p = 0.044).

Abstract: Fourteen major mutations of codon 99-191 on the RT gene were selected (K103N, V106A/M, V108I, Q151M, Y181C/I, M184V/I, Y188C/L/H, and G190S/A) at a cost of testing of 35 USD.

Abstract: The prevalence of each HIVDR mutation were

PMID: 26831472 2016 The Lancet. Infectious diseases

Abstract: <

Method: Our secondary outcomes were resistance to first generation NNRTI (efavirenz and nevirapine), defined as specific mutations at aminoacid positions 100, 103, 106, 108, 181, 188, 190, and 225, and cytosine analogue resistance, defined as presence of M184V/I.

Result: Furthermore, the M184V/I mutation was less common than NNRTI resistance across all regions except in eastern Africa.

Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.

PMID: 26899538 2016 HIV clinical trials

Abstract: One new NNRTI (Y181C) mutation was identified and three patients taking PI-based regimens developed NRTI mutations (M184 V, M184I, and T215Y).

Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk.

PMID: 26953333 2016 The Journal of antimicrobial chemotherapy

Abstract: M184V was the most common mutation associated with K65R emergence.

Browser Board

Co-occurred Entities

Filtrator